Metabolic syndrome, resistance to insulin and diabetes. What is hidden beneath the tip of the iceberg?;Sindrome metabólico, resistencia a la insulina y diabetes. ¿Qué se oculta bajo la punta del iceberg?

Atencion Primaria

Volumn 31, Issue 7, 2003, Pages 436-445

  Costa, Bernardo ^a,b,c   Cabre J J ^a   Martin F ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b Centro de Diabetes Salou   (Spain)

^c Centre Diabetis Salou   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; MOXONIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIUM CELL; FATTY LIVER; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREECLAMPSIA; REVIEW; CLINICAL TRIAL;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 0043166459     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13046946     Document Type: Review

References (58)

1. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S135-48.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1597-607.
3. Ferrannini E. Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev 1997;13:81-6.
4. Keen H, Jarret RJ, McCartney P. The ten-year follow up of the Bedford survey (1962-1972); glucose tolerance and diabetes. Diabetologia 1982;22:73-8.
5. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
6. Hunter SJ, Garvey T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction and glucose transport effector system. Am J Med 1998;5:331-46.
7. Baumgartner-Parzer SM, Wallhausl WE. The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes 2001;109 (Suppl 2):S166-79.
8. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110-6.
9. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
11. Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001;37:232-9.
12. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-8.
13. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998;21:2116-22.
14. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998;279:1477-82.
15. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
16. Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M, et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000;49:748-52.
17. Festa A, D'Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 leveles. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999;19:605-10.
18. Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis 2000;148:151-8.
19. Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 2001;86:719-23.
20. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4.
21. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001;86:5457-64.
22. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001;24:460-4.
23. Alberti KG, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
24. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
25. SEEDO (Sociedad Española para el Estudio de la Obesidad). Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000;115:587-97.
26. Matsumoto K, Sakamaki H, Izumino K, Yano M, Ueki Y, Miyake S, et al. Increased insulin sensitivity and decreased insulin secretion in offspring of insulin-sensitive type 2 diabetic patients. Metabolism 2000;49:1219-23.
27. Taniguchi A, Fukushima M, Sakai M, Kataoka K, Nagata I, Doi K, et al. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism 2000;49:1001-5.
28. Reaven GM. Insulin resistance-how important is it to treat? Exp Clin Endocrinol Diabetes 2000;108(Suppl 2):S274-80.
29. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000;49:2094-101.
30. Holness MJ, Langdown ML, Sugden MC. Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus. Biochem J 2000;349:657-65.
31. Neel JV. Diabetes mellitus: a «thrifty» genotipe rendered detrimental by «progress»? Am J Hum Genet 1962;14:353-62.
32. Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocrin J 2000;47:639-41.
33. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001;250:105-20.
34. Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
35. Targher G, Bonadonna RC, Alberiche M, Zenere MB, Muggeo M, Bonora E. Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals: role of adipose tissue. Diabetes Care 2001;24:1961-6.
36. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Kahn SE, Leonetti DL, et al. Preventing diabetes applying pathophysiological and epidemiological evidence. Br J Nutr 2000;84(Suppl 2):S173-6.
37. Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sports Med 2000;30:327-46.
38. 2 podría suponer obesidad en la población española. Med Clin (Barc) 2001;117:681-4.
39. Golub MS. The adrenal and the metabolic syndrome. Curr Hypertens Rep 2001;3:117-20.
40. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
41. Maiques Galán A. ¿Qué riesgo coronario presentan nuestros pacientes diabéticos? Aten Primaria 2002;29:205-12.
42. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:949-50.
43. Harding AH, Williams DE, Hennings SH, Mitchell J, Wareham NJ. Is the association between dietary fat intake and insulin resistance modified by physical activity? Metabolism 2001;50:1186-92.
44. McAuley KA, Williams SM, Mann JI, Goulding A, Chisholm A, Wilson N, et al. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care 2002;25:445-52.
45. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effect of diet and exercice in preventing NIDDM in people with impaired glucose tolerance: The Da Quing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
46. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
47. Costa B, Piñol JL, Donado A, Martín F, Castell C, Grupo de Investigación ITG (Reus-Tarragona). Incidencia significativa de la diabetes tipo 2 en la población española de alto riesgo. Resultados del estudio ITG(2). Med Clin (Barc) 2002;118:287-93.
48. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;12:318:1231-9.
49. Schoonjans K, Auwers J. Thiazolidinediones: an update. Lancet 2000;355:1008-10.
50. Sunayama S, Watanabe Y, Daida H, Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resístance syndrome. Curr Opin Lipidol 2000;11:397-402.
51. Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000;54:333-7.
52. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001;3:319-25.
53. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002;35:497-9.
54. Heymsfield SB, Segal KR, Haupman J. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.
55. Yusuf S, Gerstein H, Hoogwerf B, and the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
56. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:346-7.
57. Van Zwieten PA. Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens 1999;21:859-73.
58. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type 2 diabetes and obesity. Exp Clin Endocrinol Diabestes 2001;109 (Suppl 2):S189-201.